Evidence map›Paper›PMID 35813561›Full record

ArticleIJID regions2022

Genetic diversity and drug resistance profiles of

Samuel Ofori Addo, Gloria Ivy Mensah, Lydia Mosi, Afua Owusua Darkwah Abrahams, Kennedy Kwasi Addo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Utility of anti-Heliyon · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Samuel Ofori AddoDepartment of Bacteriology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
Gloria Ivy MensahDepartment of Bacteriology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
Lydia MosiDepartment of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Legon, Ghana.
Afua Owusua Darkwah AbrahamsDepartment of Pathology, University of Ghana Medical School, College of Health Sciences, University of Ghana, Legon, Ghana.
Kennedy Kwasi AddoDepartment of Bacteriology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
University of Ghana · GHNoguchi Memorial Institute for Medical Research · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study sought to determine the genetic diversity and drug resistance profiles of Methods: Spoligotyping was performed on 102 MTBC isolates from EPTB patients. Lineages/sub-lineages were assigned by comparing spoligotyping patterns primarily with the SITVIT2 database and subsequently with the TB-Lineage online tool for unknown isolates in SITVIT2. Drug susceptibility testing was performed using MGIT (BD BACTEC 960), Lowenstein-Jensen media (indirect proportion method), and GenoType MTBDR Results: Around 95% (97/102) of isolates were Conclusions: Our study confirms Cameroon (SIT61) as the most common spoligotype causing human EPTB in Ghana, and that it is associated with decreased serum IL-1β, IL-17A, and IFN-α.

Indexed as

Extrapulmonary TBGhanaLuminex immunoassayMultidrug resistanceSpoligotyping

Identifiers

PMID35813561
PMCPMC9263986
OpenAlexW4285030961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.